Prescribing overview
Cytopoint is a USDA-licensed canine biological product, not an FDA-approved oral drug.
Key prescribing checks
- Investigate the cause of itch and manage parasites, infection and other contributors as appropriate. Reduced scratching does not prove that an underlying skin problem has resolved.
- Monitor response over time. The label notes that anti-drug antibodies can sometimes reduce effectiveness in an animal that previously responded, so declining benefit warrants reassessment.
- Follow storage, injection and handling precautions for the biological product. The label notes that hypersensitivity reactions may occur; a practice should be prepared to recognize and manage an adverse reaction after administration.
- The current US insert also records uncommon post-approval neurologic events and very rare signs of immune-mediated disease. These are reported events, not proof that the product caused each case; review a relevant history with the veterinarian.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
USDA-licensed veterinary biologicalAllergic and atopic dermatitis
Dogs only.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Neutralizes soluble IL-31 to reduce itch and skin lesions.
Absorption, distribution, metabolism and elimination
Persists in canine circulation for weeks; eliminated through normal protein-degradation pathways.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Cytopoint
Dogs; subcutaneous USDA-licensed biological product
Contraindications · when not to use
- No formal contraindications are listed in the reviewed US insert.
Precautions & monitoring
- Reproductive safety has not been tested. Hypersensitivity, neurologic and immune-mediated events have been reported; antibodies may reduce response.
Absence of a listed contraindication does not establish safety for every patient.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Reported events include hypersensitivity, GI upset, seizures/ataxia and immune-mediated disease; reports do not establish causation.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsAllergic/atopic dermatitisCytopoint injection | Minimum 2 mg/kg Subcutaneous only · Every 4–8 weeks as needed Individualized | Use label weight-band vials; <5 lb: 0.2 mL/kg of 10 mg/mL vial. Verify full dosing label ↗ |
Not tested in breeding, pregnant or lactating animals.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Cytopoint
Dogs; subcutaneous USDA-licensed biological product
- Do not mix with other products.
Monitoring
Track itch/lesions and declining response; persistent anti-drug antibodies may reduce benefit.
Client counseling
Seek prompt help for facial swelling, collapse or breathing difficulty.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store upright at 2–8°C; do not freeze. Single-use vials; do not mix products.
Brands, formulations & ingredient identity
Active ingredients
Lokivetmab
Cytopoint is not another brand of Apoquel: lokivetmab is an antibody, while Apoquel contains oclacitinib. These names must resolve to different entries.
In the United States, Cytopoint is a USDA-licensed biological product, not an FDA-approved oral drug. The label’s canine indication must not be generalized to cats or other species.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Cytopoint
- Formulation
- Subcutaneous injectable biological product
- Label / product scope
- Dogs
Canine dermatitis immunotherapeutic; USDA-licensed in the US.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →